[1]李梦琦,李长忠.散结镇痛胶囊联合地诺孕素对子宫内膜异位症患者血清EMAb、CA125的影响[J].西部中医药,2024,37(12):140-142.[doi:10.12174/j.issn.2096-9600.2024.12.33]
　LI Mengqi,LI Changzhong.Effects of Nodulus-eliminating Pain-relieving Capsules Combined with Dienogest on Serum EMAb and CA125 in Patients with Endometriosis[J].Western Journal of Traditional Chinese Medicine,2024,37(12):140-142.[doi:10.12174/j.issn.2096-9600.2024.12.33]
点击复制

散结镇痛胶囊联合地诺孕素对子宫内膜异位症患者血清EMAb、CA125的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年12期
页码:
140-142
栏目:
临床研究
出版日期:
2024-12-15

文章信息/Info

Title:
Effects of Nodulus-eliminating Pain-relieving Capsules Combined with Dienogest on Serum EMAb and CA125 in Patients with Endometriosis
作者:
李梦琦1, 李长忠2
1.山东中医药大学，山东 济南 250011
2.山东省立医院，山东 济南 250011
Author(s):
LI Mengqi1, LI Changzhong2
1.Shandong University of Traditional Chinese Medicine, Jinan 250011, China
2.Shandong Provincial Hospital, Jinan 250011, China
关键词:
子宫内膜异位症; 散结镇痛胶囊; 地诺孕素; 抗子宫内膜抗体; 糖类抗原125
Keywords:
endometriosis; nodulus-eliminating pain-relieving capsules; dienogest; anti-endometrial antibody; carbohydrate antigen
分类号:
R271.11
DOI:
10.12174/j.issn.2096-9600.2024.12.33
文献标志码:
B
摘要:
目的观察应用散结镇痛胶囊联合地诺孕素治疗子宫内膜异位症（endometriosis，EMT）的临床疗效及其对血清抗子宫内膜抗体（anti-endometrial antibody，EMAb）、糖类抗原125（carbohydrate antigen，CA125）的影响。 方法选择EMT患者60例，随机分为观察组和对照组，每组30例。观察组给予散结镇痛胶囊联合地诺孕素治疗，对照组给予地诺孕素治疗，共治疗6个月经周期。对比两组治疗前后视觉模拟评分（visual analogue score，VAS）评分及血清EMAb转阴率、血清CA125水平，评估两组临床疗效。 结果治疗后观察组总有效率［90.00%（27/30）］高于对照组［66.67%（20/30）］（P＜0.05）；观察组EMAb转阴率［76.67%（23/30）］高于对照组［46.67%（14/30）］（P＜0.05）。治疗后两组VAS评分及血清CA125水平均较治疗前下降（P＜0.05），且观察组下降程度大于对照组（P＜0.05）。 结论散结镇痛胶囊联合地诺孕素治疗EMT临床疗效明显，可有效降低CA125水平，提高EMAb转阴率且无严重不良反应。
Abstract:
ObjectiveTo observe clinical effects of Sanjie Zhentong capsules (nodulus-eliminating pain-reliev-ing capsules) joined with dienogest in the treatment of endometriosis and its influence on the levels of anti-endometrial antibody (EMAb) and carbohydrate antigen (CA125). MethodsSixty patients were chosen and randomized into the observation group and the control group, 30 cases in each group. The observation group was treated with nodulus-eliminating pain-relieving capsules and dienogest, and dienogest was administered to the control group. All the patients were treated for six menstrual cycles. To compare VAS scores, the conversion rate of serum EMAb and the levels of serum CA125 before and after the treatment in the two groups, to assess clinical effects between both groups. ResultsAfter the treatment, total effective rate of the observation group was [90.00%(27/30)], higher than [66.67%(20/30)] of the control group (P<0.05); the conversion rate of EMAb of the observa-tion group was [76.67%(23/30)], higher than [46.67%(14/30)] of the control group (P<0.05). After the treatment, VAS scores and the levels of serum CA125 were lower in the two groups than before the treatment (P<0.05), and the decrease of the observation group was greater than that of the control group (P<0.05). ConclusionNodulus-eliminating pain-relieving capsules and dienogest could obtain noticeable clinical effects in the treatment of endometriosis, which could effectively reduce the levels of CA125, increase EMAb conversiun rate without severe adverse reactions.

相似文献/References:

[1]王颖.辨证论治子宫内膜异位症118例[J].西部中医药,2013,26(12):85.
　WANG Ying.Syndrome Differentiation and Treatment for 118 Cases of Endometriosis[J].Western Journal of Traditional Chinese Medicine,2013,26(12):85.
[2]葛慧娟,曹保利.子宫内膜异位症术后应用复方莪术散的疗效观察[J].西部中医药,2014,27(04):100.
　GE Huijuan,CAO Baoli.Clinical Observation on Compound EZhu Powder Applied to the Patients after the Surgery of Endometriosis[J].Western Journal of Traditional Chinese Medicine,2014,27(12):100.
[3]李红霞,万国蕊,徐静,等.三花益肾汤治疗子宫内膜异位症临床观察[J].西部中医药,2015,28(01):7.
[4]陆建英,董莉,谭蕾,等.朱南孙治疗子宫内膜异位症经验举隅*[J].西部中医药,2013,26(10):42.
　LU Jianying,DONG Li,TAN Lei,et al.Examples of Zhu Nansun Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2013,26(12):42.
[5]董迹菲,翟培杞,孙炜,等.基于数据挖掘的针灸治疗子宫内膜异位症选穴配伍规律的文献研究[J].西部中医药,2015,28(06):86.[doi:2015/6/16 0:00:00]
[6]胡淑寒,曹保利△,刘霞,等.中药治疗子宫内膜异位症的用药规律研究[J].西部中医药,2018,31(09):87.
　HU Shuhan,CAO Baoli,LIU Xia,et al.Drug Use Law of Traditional Chinese Medicine in Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2018,31(12):87.
[7]唐晓琳,石璇△.中药治疗子宫内膜异位症的临床效果[J].西部中医药,2017,30(01):66.
　TANG Xiaolin,SHI Xuan.Clinical Effects of Chinese Materia Medica in Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2017,30(12):66.
[8]刘帅,曹保利.莪术油对大鼠子宫内膜异位症基质细胞衍生因子-1及其受体表达的影响[J].西部中医药,2018,31(03):26.
　LIU Shuai,CAO Baoli.The Effects of Curcuma Zedoary Oil on the Expressions of Stromal Cell Derived Factor-1 and Its Receptor in Endometriosis Rats Model[J].Western Journal of Traditional Chinese Medicine,2018,31(12):26.
[9]徐群群,卢敏,曹阳,等.清热化瘀法对子宫内膜异位症患者血管生成机制的影响[J].西部中医药,2019,32(02):1.
　XU Qunqun,LU Min,CAO Yang,et al.The Effects of Heat-clearing Stasis-eliminating Method on the Mechanism of Angiogenesis of Endometriosis Patients[J].Western Journal of Traditional Chinese Medicine,2019,32(12):1.
[10]张彩凤.益肾汤联合孕三烯酮治疗子宫内膜异位症[J].西部中医药,2019,32(03):87.
　ZHANG Caifeng.Kidney-nourishing Decoction Combined with Gestrinone in Treating Endometriosis[J].Western Journal of Traditional Chinese Medicine,2019,32(12):87.
[11]赵秀萍,马小娜,郭亚楠.基于网络药理学及分子对接探讨散结镇痛胶囊治疗子宫内膜异位症的分子机制[J].西部中医药,2024,37(02):77.[doi:10.12174/j.issn.2096-9600.2024.02.16]
　ZHAO Xiuping,MA Xiaona,GUO Yana.Exploration into the Molecular Mechanism of Sanjie Zhentong Capsulse in the Treatment of Endometriosis Based on Network Pharmacology and Molecular Docking[J].Western Journal of Traditional Chinese Medicine,2024,37(12):77.[doi:10.12174/j.issn.2096-9600.2024.02.16]

备注/Memo

备注/Memo:
李梦琦（1996—），女，硕士学位。研究方向：妇科疾病的中西医结合治疗。国家自然科学基金（81671634）。
更新日期/Last Update: 2024-12-15